Effect of thiazolidinedione treatment on proteinuria and renal hemodynamic in type 2 diabetic patients with overt nephropathy

Hormone and Metabolic Research

Volumn 44, Issue 12, 2012, Pages 914-918

  Pistrosch, F ^a   Passauer, J ^a   Herbrig, K ^a   Schwanebeck, U ^b   Gross, P ^a   Bornstein, S R ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

diabetic nephropathy; nitric oxide; proteinuria; thiazolidinedione; type 2 diabetes

Indexed keywords

ALBUMIN; DIURETIC AGENT; N(G) METHYLARGININE; NITRIC OXIDE; PLACEBO; ROSIGLITAZONE;

AGED; ARTICLE; BIOAVAILABILITY; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; DIABETIC NEPHROPATHY; DIABETIC PATIENT; DRUG DOSE REDUCTION; DRUG TOLERABILITY; FAINTNESS; FEMALE; GLOMERULUS FILTRATION RATE; HEMODYNAMICS; HUMAN; KIDNEY BLOOD FLOW; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL EDEMA; PRIORITY JOURNAL; PROTEINURIA; RENAL PROTECTION; SIDE EFFECT; THERAPY EFFECT; WEIGHT GAIN;

AGED; AGED, 80 AND OVER; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEMODYNAMICS; HUMANS; HYPOGLYCEMIC AGENTS; KIDNEY; MALE; MIDDLE AGED; PILOT PROJECTS; PPAR GAMMA; PROTEINURIA; RENAL CIRCULATION; SEVERITY OF ILLNESS INDEX; THIAZOLIDINEDIONES;

EID: 84869487794     PISSN: 00185043     EISSN: 14394286     Source Type: Journal    
DOI: 10.1055/s-0032-1314836     Document Type: Article

References (26)

1. Hemmelgarn B. R., Manns B. J., Lloyd A., James M. T., Klarenbach S., Quinn R. R., Wiebe N., Tonelli M. Relation between kidney function, proteinuria, and adverse outcomes. JAMA: 2010; 303 423 429
2. Deckert T., Feldt-Rasmussen B., Borch-Johnsen K., Jensen T., Kofoed-Enevoldsen A. Albuminuria reflects widespread vascular damage. The steno hypothesis. Diabetologia: 1989; 32 219 226
3. Lewis E. J., Hunsicker L. G., Bain R. P., Rohde R. D. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med: 1993; 329 1456 1462
4. Lewis E. J., Hunsicker L. G., Clarke W. R., Berl T., Pohl M. A., Lewis J. B., Ritz E., Atkins R. C., Rohde R., Raz I. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med: 2001; 345 851 860
5. Ruggenenti P., Fassi A., Ilieva A. P., Bruno S., Iliev I. P., Brusegan V., Rubis N., Gherardi G., Arnoldi F., Ganeva M., Ene-Iordache B., Gaspari F., Perna A., Bossi A., Trevisan R., Dodesini A. R., Remuzzi G. Preventing microalbuminuria in type 2 diabetes. N Engl J Med: 2004; 351 1941 1951
6. Karalliedde J., Viberti G. Proteinuria in diabetes: bystander or pathway to cardiorenal disease? J Am Soc Nephrol: 2010; 21 2020 2027
7. Bakris G., Viberti G., Weston W. M., Heise M., Porter L. E., Freed M. I. Rosiglitazone reduces urinary albumin excretion in type II diabetes. J Hum Hypertens: 2003; 17 7 12
8. Pistrosch F., Herbrig K., Kindel B., Passauer J., Fischer S., Gross P. Rosiglitazone improves glomerular hyperfiltration, renal endothelial dysfunction, and microalbuminuria of incipient diabetic nephropathy in patients. Diabetes: 2005; 54 2206 2211
9. Sarafidis P. A., Bakris G. L. Protection of the kidney by thiazolidinediones: an assessment from bench to bedside. Kidney Int: 2006; 70 1223 1233
10. Cole B. R., Giangiacomo J., Ingelfinger J. R., Robson A. M. Measurement of renal function without urine collection. A critical evaluation of the constant-infusion technic for determination of inulin and para-aminohippurate. N Engl J Med: 1972; 287 1109 1114
11. Delles C., Jacobi J., John S., Fleischmann I., Schmieder R. E. Effects of enalapril and eprosartan on the renal vascular nitric oxide system in human essential hypertension. Kidney Int: 2002; 61 1462 1468
12. Smith H. W., Finkelstein N., Aliminosa L., Crawford B., Graber M. The renal clearences of substituted hippuric acid derivates and other aromatic acids in dog and man. J Clin Invest: 1945; 24 388 404
13. White R. P., Samson F. E. Jr. Determination of inulin in plasma and urine by use of anthrone. J Lab Clin Med: 1954; 43 475 478
14. Sarafidis P. A., Stafylas P. C., Georgianos P. I., Saratzis A. N., Lasaridis A. N. Effect of thiazolidinediones on albuminuria and proteinuria in diabetes: a meta-analysis. Am J Kidney Dis: 2010; 55 835 847
15. Natali A., Baldeweg S., Toschi E., Capaldo B., Barbaro D., Gastaldelli A., Yudkin J. S., Ferrannini E. Vascular effects of improving metabolic control with metformin or rosiglitazone in type 2 diabetes. Diabetes Care: 2004; 27 1349 1357
16. Pistrosch F., Passauer J., Fischer S., Fuecker K., Hanefeld M., Gross P. In type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control. Diabetes Care: 2004; 27 484 490
17. Rudofsky G. Jr, Reismann P., Grafe I. A., Konrade I., Djuric Z., Tafel J., Buchbinder S., Zorn M., Humpert P. M., Hamann A., Morcos M., Nawroth P. P., Bierhaus A. Improved vascular function upon pioglitazone treatment in type 2 diabetes is not associated with changes in mononuclear NF-kappaB binding activity. Horm Metab Res: 2007; 39 665 671
18. Agarwal R., Saha C., Battiwala M., Vasavada N., Curley T., Chase S. D., Sachs N., Semret M. H. A pilot randomized controlled trial of renal protection with pioglitazone in diabetic nephropathy. Kidney Int: 2005; 68 285 292
19. Feldman L., Shani M., Efrati S., Beberashvili I., Baevsky T., Weissgarten J., Vinker S. Association between rosiglitazone use and decline in renal function in patients with type 2 diabetes mellitus. J Nephrol: 2010; 23 350 356
20. Schneider C. A., Ferrannini E., Defronzo R., Schernthaner G., Yates J., Erdmann E. Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease. J Am Soc Nephrol: 2008; 19 182 187
21. Yang H. C., Deleuze S., Zuo Y., Potthoff S. A., Ma L. J., Fogo A. B. The PPARgamma agonist pioglitazone ameliorates aging-related progressive renal injury. J Am Soc Nephrol: 2009; 20 2380 2388
22. Benigni A., Zoja C., Tomasoni S., Campana M., Corna D., Zanchi C., Gagliardini E., Garofano E., Rottoli D., Ito T., Remuzzi G. Transcriptional regulation of nephrin gene by peroxisome proliferator-activated receptor-gamma agonist: molecular mechanism of the antiproteinuric effect of pioglitazone. J Am Soc Nephrol: 2006; 17 1624 1632
23. Ohga S., Shikata K., Yozai K., Okada S., Ogawa D., Usui H., Wada J., Shikata Y., Makino H. Thiazolidinedione ameliorates renal injury in experimental diabetic rats through anti-inflammatory effects mediated by inhibition of NF-kappaB activation. Am J Physiol Renal Physiol: 2007; 292 F1141 F1150
24. Zheng F., Fornoni A., Elliot S. J., Guan Y., Breyer M. D., Striker L. J., Striker G. E. Upregulation of type I collagen by TGF-beta in mesangial cells is blocked by PPARgamma activation. Am J Physiol Renal Physiol: 2002; 282 F639 F648
25. Karalliedde J., Buckingham R., Starkie M., Lorand D., Stewart M., Viberti G. Effect of various diuretic treatments on rosiglitazone-induced fluid retention. J Am Soc Nephrol: 2006; 17 3482 3490
26. Kaul S., Bolger A. F., Herrington D., Giugliano R. P., Eckel R. H. Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart Association and American College of Cardiology Foundation. Circulation: 2010; 121 1868 1877